Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores

Background There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clinic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Clinical Laboratory Analysis 2021-08, Vol.35 (8), p.e23880-n/a
Main Authors: Yao, Renling, Zhu, Li, Wang, Jian, Liu, Jiacheng, Xue, Ruifei, Xue, Leyang, Liu, Longgen, Li, Chunyang, Zhao, Haiyan, Cheng, Juan, Huang, Songping, Li, Yang, Zhao, Xiang‐an, Zhu, Chuanwu, Li, Ming, Huang, Rui, Wu, Chao
Format: Article
Language:English
Subjects:
Age
Body mass index
Chronic illnesses
Clinical outcomes
Comorbidity
Coronaviruses
COVID-19
Diabetes
Diabetes mellitus
Fatty liver
Fibrosis
Hepatitis B
Hepatitis C
Hospitals
Hypertension
Laboratories
Liver diseases
Lung diseases
Multivariate analysis
non‐alcoholic fatty liver disease
Patients
Pneumonia
Regression analysis
Risk factors
Severe acute respiratory syndrome coronavirus 2
severe illness
Steatosis
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clinical outcomes of COVID‐19 patients with NAFLD. Methods The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis. Results A total of 86 COVID‐19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty‐eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202–56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193–102.439, p = 0.034) were independent risk factors of severe illness in COVID‐19 patients with NAFLD. Conclusion NAFLD patients with NFS‐determined advanced liver fibrosis are at higher risk of severe COVID‐19. Concurrent with NAFLD is common in COVID‐19 patients. The presence of advanced liver fibrosis was an independent risk factor of severe illness in COVID‐19 patients with NAFLD.
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.23880